This company, based in Germany, operates as a biopharmaceutical firm that engaged in the development of messenger RNA (mRNA) therapeutics. It was established in 2000 and has registered headquarters located in Tuebingen. It is the leading mRNA company with unique expertise and know-how for the production and therapeutic application of mRNA. It offers RNActive, which are mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases; RNArt molecular therapies that are designed to trigger the body's own production of therapeutic proteins; and RNAdjuvant RNA encoded antibodies. The company also researches and develops active ingredients for the treatment of cancer, as well as for protection against infectious diseases; and RNActive-based rabies vaccines.
The read only version of the questionnaire submitted to this company is publicly available: view questionnaire.